Joint USPTO-FDA Public Listening Session on Collaboration Initiatives

The United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) have issued a Federal Register Notice announcing a joint public listening session and requesting written comments on areas for collaboration and engagement between the agencies.

The USPTO proposed collaboration initiatives in a July 6 letter to the FDA. These initiatives aim to enhance collaboration between USPTO and FDA to ensure that our innovation system strikes the appropriate balance—encouraging meaningful innovation in drug development and supporting a competitive marketplace that can promote greater access to medicines for American families. To facilitate stakeholder feedback on these initiatives, this notice sets forth questions on various collaboration topics.

If you have any questions, please contact Starr Baker (starr.baker@uspto.gov).

The event will be available for viewing virtually, however, speakers must attend in person at the USPTO headquarters in Alexandria, Virginia.

Register for in person  Register for virtual

Read the full text of the notice on the USPTO-FDA collaboration initiatives webpage. Information about the collaborative efforts can be read in the USPTO’s joint blog with the FDA.

Accessibility

If you are an individual with a disability and would like to request a reasonable accommodation, please submit your request to the contact information listed above.

CLE Header
This event is part of a series: USPTO-FDA joint initiative